X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (37) 37
index medicus (31) 31
humans (27) 27
female (21) 21
middle aged (20) 20
aged (19) 19
adult (16) 16
melanoma (14) 14
chemotherapy (13) 13
ovarian cancer (12) 12
ovarian neoplasms - drug therapy (12) 12
cancer (10) 10
multicenter (10) 10
open-label (10) 10
aged, 80 and over (9) 9
antineoplastic agents - therapeutic use (9) 9
germ-line mutation (9) 9
immunotherapy (9) 9
male (9) 9
survival (9) 9
melanoma - pathology (8) 8
ovarian neoplasms - genetics (8) 8
poly polymerase (8) 8
treatment outcome (8) 8
antineoplastic agents - adverse effects (7) 7
brca1 protein - genetics (7) 7
brca2 protein - genetics (7) 7
care and treatment (7) 7
ipilimumab (7) 7
metastasis (7) 7
ovarian neoplasms - pathology (7) 7
patients (7) 7
phthalazines - adverse effects (7) 7
phthalazines - therapeutic use (7) 7
piperazines - adverse effects (7) 7
piperazines - therapeutic use (7) 7
tumors (7) 7
analysis (6) 6
carcinoma (6) 6
melanoma - therapy (6) 6
metastatic melanoma (6) 6
mutation (6) 6
neoplasm staging (6) 6
prognosis (6) 6
retrospective studies (6) 6
solid tumors (6) 6
disease-free survival (5) 5
hematology, oncology and palliative medicine (5) 5
immunology (5) 5
interleukin-2 (5) 5
kaplan-meier estimate (5) 5
lymphocytes, tumor-infiltrating - immunology (5) 5
melanoma - drug therapy (5) 5
olaparib (5) 5
ovarian neoplasms - mortality (5) 5
pembrolizumab (5) 5
therapy (5) 5
toxicity (5) 5
young adult (5) 5
abridged index medicus (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
breast-cancer (4) 4
clinical trials (4) 4
genes, brca1 (4) 4
genes, brca2 (4) 4
genetic aspects (4) 4
melanoma - immunology (4) 4
neoplasm grading (4) 4
neoplasm metastasis (4) 4
neoplasm recurrence, local - drug therapy (4) 4
nivolumab (4) 4
obstetrics & gynecology (4) 4
platinum (4) 4
poly polymerase inhibitors - therapeutic use (4) 4
relapse (4) 4
repair (4) 4
responses (4) 4
skin neoplasms - drug therapy (4) 4
survival analysis (4) 4
trial (4) 4
tumor-infiltrating lymphocytes (4) 4
adoptive cell transfer (3) 3
antineoplastic agents - administration & dosage (3) 3
apoptosis (3) 3
article (3) 3
biomarkers (3) 3
brca (3) 3
brca1 protein (3) 3
breast cancer (3) 3
cancer regression (3) 3
cancer therapies (3) 3
clinical medicine (3) 3
cutaneous melanoma (3) 3
diseases (3) 3
double-blind method (3) 3
drug resistance, neoplasm (3) 3
drug therapy (3) 3
expression (3) 3
fallopian-tube (3) 3
immunotherapy, adoptive (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 908 - 918
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 11, pp. 1579 - 1589
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 26, pp. 2521 - 2532
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2012, Volume 366, Issue 15, pp. 1382 - 1392
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 852 - 861
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2015, Volume 33, Issue 3, pp. 244 - 250
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4095 - 4106
Journal Article
Journal Article
The Oncologist, ISSN 1083-7159, 05/2019, Volume 24, Issue 5, pp. 640 - 647
Immune checkpoint inhibitors are associated with a unique profile of adverse events that can affect many organ systems. One of them is immune‐mediated... 
Immune checkpoint inhibitors | Pneumonitis | Recurrent pneumonitis | Immune‐related adverse events | SURVIVAL | MULTICENTER | Immune-related adverse events | MANAGEMENT | COMBINED NIVOLUMAB | OPEN-LABEL | COMBINATION | CANCER-PATIENTS | PEMBROLIZUMAB | ONCOLOGY | ANTI-PD-1 | IPILIMUMAB
Journal Article
European Journal of Cancer, ISSN 0959-8049, 09/2018, Volume 101, pp. 229 - 235
BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) are among the cornerstones of metastatic melanoma therapy demonstrating excellent response rates with... 
Metastatic melanoma | BRAF inhibitor melanoma | Immune-related adverse events | Targeted Therapy | SURVIVAL | MULTICENTER | MONOTHERAPY | OPEN-LABEL | PHASE-3 | DABRAFENIB PLUS TRAMETINIB | PEMBROLIZUMAB | ONCOLOGY | CUTANEOUS MELANOMA | ASSOCIATION | VEMURAFENIB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Arthralgia - chemically induced | Young Adult | Pyridones - administration & dosage | Vemurafenib - administration & dosage | Neoplasm Metastasis | Melanoma - genetics | Aged, 80 and over | Adult | Female | Retrospective Studies | Vemurafenib - adverse effects | Skin Neoplasms - pathology | MAP Kinase Kinase 1 - antagonists & inhibitors | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Kaplan-Meier Estimate | MAP Kinase Kinase 1 - metabolism | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Azetidines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Skin Neoplasms - genetics | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Complications and side effects | Care and treatment | Immune response | Analysis | Immunotherapy | Melanoma | Metastasis | Therapy | Keratitis | MEK inhibitors | Medical treatment | Medical services | Lactate dehydrogenase | Regression analysis | Patients | L-Lactate dehydrogenase | Metastases | Vitiligo | Inhibitors | Uveitis | Biomarkers | Bioindicators | Lactic acid | Erythema nodosum | Erythema | Index Medicus
Journal Article